Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 75

HL-1186 Tablet for postoperative pain after abdominal surgery

Official title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Parallel-Group Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablets for Postoperative Analgesia in Abdominal Surgery

Run by Shanghai Huilun Pharmaceutical Co., Ltd. · NCT07709598 · Data updated 2026-11-12

This trial tests HL-1186 tablets to see if they reduce pain after abdominal surgery compared with placebo and an oxycodone-acetaminophen option.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment330 (estimated)
SponsorShanghai Huilun Pharmaceutical Co., Ltd.
Industry-sponsored
Locations1 site (Chengdu, Sichuan)
StatusRecruiting
StartedMay 11, 2026
Main results expectedOctober 2026
Study endsDecember 2026
Registry record updatedJuly 16, 2026
Trial IDNCT07709598 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to 75 undergoing abdominal surgery under general anesthesia with anticipated moderate-to-severe postoperative pain and the ability to use pain scales.

Probably not a fit

Patients with prior surgery at the same site, neuropsychological issues, or certain cardiac or respiratory conditions may not experience benefit or could be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind trial with parallel groups designed to test the safety and effectiveness of HL-1186 tablets for postoperative analgesia after abdominal surgery. It includes phase II and phase III components, comparing HL-1186 to placebo and to an active comparator (oxycodone-acetaminophen), with a parallel-group design and blinded assessment. Eligible patients are adults 18 to 75 undergoing abdominal surgery under general anesthesia and experiencing moderate to severe pain after surgery. Key outcomes focus on pain relief and safety, including postoperative pain scores and adverse events. The study is sponsored by Shanghai Huilun Pharmaceutical Co., with a participating site at Sichuan Provincial People's Hospital in Chengdu.

Why it matters

Potential benefit: If successful, HL-1186 could provide effective postoperative pain relief with a favorable safety profile.

How similar studies have gone: Previous studies in similar analgesic approaches have shown promise, but this exact HL-1186 strategy is being evaluated in a combined Phase II/III trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 18 years old ≤ age ≤ 75 years old, gender is not limited.
2. 18 kg/m2 ≤ Body Mass Index (BMI) ≤ 30kg/m2.
3. Scheduled to undergo abdominal surgery under general anesthesia, with expected moderate-to-severe postoperative pain intensity.
4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.
5. After surgery completion, the participant is judged by the investigator to be awake and has a resting NRS score ≥ 4.

Exclusion Criteria:

1. Previous surgery on the same site that may affect pain perception at the surgical site.
2. Paresthesia or other pain that may affect postoperative pain evaluation or scale assessment.
3. Neuropsychological disorders that may affect postoperative pain evaluation or scale assessment.
4. Unstable angina, myocardial infarction, severe arrhythmia, NYHA cardiac function class ≥ III, or recurrent asthma attacks, etc., deemed unsuitable for inclusion by the investigator.
5. Poorly controlled hypertension.
6. Sleep apnea syndrome, or the presence of a difficult airway as assessed by the investigator.
7. Known allergy to any component of the investigational drug(s), to perioperative (from induction of anesthesia to completion of surgery) anesthetic/analgesic/antiemetic drugs, or a history of allergy to ≥ 3 substances.
8. Positive for human immunodeficiency virus (HIV) antibody; positive for Treponema pallidum antibody and positive toluidine red unheated serum test (TRUST); positive for hepatitis B surface antigen (HBsAg) with detectable HBV-DNA; or positive for hepatitis C virus (HCV) antibody.
9. Women who are pregnant or breastfeeding (within 1 year after delivery).
10. Participation in another drug or medical device trial within 1 month before screening, or currently participating in another clinical trial receiving investigational intervention.
11. Any other condition considered unsuitable for participation by the investigator.

Where it's running

  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.